CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 252 enrolled / 252 target
Drug / intervention
Observationother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04566432
NCT04566432N/ACompletedOn Track (3.5/mo)Completion was 6mo ago
CompareCT.gov

Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients Treated With Immune Checkpoint Inhibitors (ICIs) or Targeted Therapy

Geneplus-Beijing Co. Ltd.·observational·Posted Sep 28, 2020·Updated Jun 29, 2026

In Brief

An observational study evaluating Observation for Lung Neoplasms and 3 related conditions. Completed, enrolled 252 participants across 1 site.

Detailed Summary

To evaluate the predictive value of ctDNA in response, relapse for patients treated with immune checkpoint inhibitors or targeted therapy for ALK, ROS1, MET ex14 skipping.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsLung Neoplasms, Lung Cancer, Nonsmall Cell, Adenocarcinoma of Lung, Squamous Cell Lung Cancer
CountriesChina
CollaboratorsShanghai Chest Hospital

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedSep 28, 2020
Enrollment StartJul 1, 2020
Primary CompletionDec 31, 2025
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 5.8 years ago

Arms & Interventions

Immune checkpoint inhibitorsother

Other: Observation
Targeted therapyother

Targeting ALK, ROS1, MET ex14 skipping

Other: Observation

Interventions

Observationother

observe the association of ctDNA with efficacy of treatment